Abstract
Background: Anti- John Cunningham virus (JCV) antibody index has been reported to correlate with progressive multifocal leukoencephalopathy (PML) risk in seropositive Multiple Sclerosis (MS) patients. Although it is reported that seroconversion occurs in approximately 2–15% of patients per year, there is insufficient evidence on long-term dynamics of anti-JCV antibody index. Our objective was to investigate the longitudinal evolution of anti-JCV antibody index in a cohort of Tunisian MS patients and to evaluate the impact of age, sex and disease modifying therapies (DMT) use in Anti-JCV antibody status.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
